| UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. | | UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. | Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Nor | 2018-05-06T22:00:00Z | <p style="text-align:justify;"><strong class="ms-rteThemeFontFace-1 ms-rteFontSize-2">Abstract</strong></p><p style="text-align:justify;"><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2" style="color:#222222;letter-spacing:0.17000000178813934px;background-color:#ffffff;">The histone H3 Lys27-specific demethylase UTX (or KDM6A) is targeted by loss-of-function mutations in multiple cancers. Here, we demonstrate that UTX suppresses myeloid leukemogenesis through noncatalytic functions, a property shared with its catalytically inactive Y-chromosome paralog, UTY (or KDM6C). In keeping with this, we demonstrate concomitant loss/mutation of </span><em class="ms-rteThemeFontFace-1 ms-rteFontSize-2">KDM6A</em><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2" style="color:#222222;letter-spacing:0.17000000178813934px;background-color:#ffffff;"> (</span><em class="ms-rteThemeFontFace-1 ms-rteFontSize-2">UTX</em><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2" style="color:#222222;letter-spacing:0.17000000178813934px;background-color:#ffffff;">) and </span><em class="ms-rteThemeFontFace-1 ms-rteFontSize-2">UTY</em><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2" style="color:#222222;letter-spacing:0.17000000178813934px;background-color:#ffffff;"> in multiple human cancers. Mechanistically, global genomic profiling showed only minor changes in H3K27me3 but significant and bidirectional alterations in H3K27ac and chromatin accessibility; a predominant loss of H3K4me1 modifications; alterations in ETS and GATA-factor binding; and altered gene expression after </span><em class="ms-rteThemeFontFace-1 ms-rteFontSize-2">Utx</em><span class="ms-rteThemeFontFace-1 ms-rteFontSize-2" style="color:#222222;letter-spacing:0.17000000178813934px;background-color:#ffffff;"> loss. By integrating proteomic and genomic analyses, we link these changes to UTX regulation of ATP-dependent chromatin remodeling, coordination of the COMPASS complex and enhanced pioneering activity of ETS factors during evolution to AML. Collectively, our findings identify a dual role for UTX in suppressing acute myeloid leukemia via repression of oncogenic ETS and upregulation of tumor-suppressive GATA programs.</span><br></p> | <p><a href="https://www.nature.com/articles/s41588-018-0114-z">Nat Genet (2018) 50:883-894.</a><br></p> | 192 | | |
